Home › Funds › Portolan Capital Management, LLC › BIO

Portolan Capital Management, LLC position in BIO

BIO RAD LABS INC · Industrials

Portolan Capital Management, LLC reported holding 55,797 shares of BIO (BIO RAD LABS INC) in its Q3 2026 13F filing — a position valued at US$21.1M, representing 0.88% of its reported portfolio and ranking #43 among its reported holdings. Portolan Capital Management, LLC has disclosed BIO holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)55.80K sh
Reported value held$21.08M
Portfolio Weight0.88%
First reportedQ3 2023
Last changeAdd
Updated2026-11-17

Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR

How Portolan Capital Management, LLC's BIO position evolved

Portolan Capital Management, LLC first disclosed a stake in BIO in Q3 2023 at 42,486 shares (US$15.2M). The position peaked in Q1 2024 at 90,992 shares, worth US$31.5M. Across 13 filings, Portolan Capital Management, LLC increased the stake 6 time(s), trimmed it 6 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 55,797 shares valued at US$21.1M — an increase of 13,177 shares quarter over quarter.. Notable position changes include a 72% trim in Q2 2024 (shares rose 23% over the following quarter), a 189% increase in Q2 2025 (shares rose 16% over the following quarter), a 201% increase in Q2 2026 (shares rose 29% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 42.49K $15.23M New
Q4 2023 57.27K $18.49M Add
Q1 2024 90.99K $31.47M Add
Q2 2024 25.15K $6.87M Reduce
Q3 2024 21.90K $7.33M Reduce
Q4 2024 30.59K $10.05M Add
Q1 2025 21.74K $5.29M Reduce
Q2 2025 62.78K $15.15M Add
Q3 2025 46.44K $13.02M Reduce
Q4 2025 34.16K $10.35M Reduce
Q1 2026 14.17K $3.95M Reduce
Q2 2026 42.62K $12.51M Add
Q3 2026 55.80K $21.08M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About BIO and 13F data

BIO (BIO RAD LABS INC) is a Industrials company. 27 other funds we track also report a position in BIO — the largest reported positions include First Eagle Investment Management (US$927.5M), ARIEL INVESTMENTS, LLC (US$298.1M), EARNEST PARTNERS LLC (US$214.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding BIO

All BIO fund holders →

FAQ

How long has Portolan Capital Management, LLC held BIO?

Portolan Capital Management, LLC has disclosed BIO holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Portolan Capital Management, LLC's current position in BIO?

As of Q3 2026, Portolan Capital Management, LLC holds 55.80K shares of BIO (BIO RAD LABS INC), valued at $21.08M, representing 0.88% of its reported portfolio and ranking #43.

Has Portolan Capital Management, LLC been buying or selling BIO?

In the latest 13F filing (Q3 2026), Portolan Capital Management, LLC increased its position in BIO. The position peaked in Q1 2024 at 90.99K shares.

Which other funds hold BIO?

Other major institutional holders of BIO include First Eagle Investment Management, ARIEL INVESTMENTS, LLC, EARNEST PARTNERS LLC, among 27 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.